DOCK5

本研究考察健康受试者在空腹及餐后条件下，单次口服由湖南洞庭药业股份有限公司生产的阿普唑仑片（受试制剂，规格：0.4 mg）或由ヴィアトリス製薬株式会社（Viatoris制药株式会社）持证的阿普唑仑片（参比制剂，商品名：Solanax®，规格：0.4 mg）的药动学特征，评价两制剂的生物等效性及安全性，该受试制剂一致性评价提供依据。

The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will be asked to remain seated with their head inside of a Magnetoencephalography (MEG) recording system as resting-state and task-related data are acquired. Spontaneous electrophysiological activity will be recorded in both the eyes open and eyes closed conditions with the participant seated comfortably. These recordings will be repeated in the DBS OFF and DBS ON states, with the ON state involving specific settings identified as optimal, sub-optimal, or ineffective at achieving tremor control. They will also be repeated following the optional administration non-DBS tremor mitigation techniques, which may include one or more of 1) cooling the limb, 2) oral administration of alprazolam, 3) oral consumption of ethanol (alcohol), or 4) peripheral nerve stimulation.